SOPHIA BIOSCIENCE

Sophia Bioscience develops new pharmaceutical treatments for early and metastatic cancers. It aims to increase the effectiveness of established drugs while lowering their required dosage and minimizing side effects. Sophia Bioscience also works to improve the drug development process, shortening the time to develop and significantly lowering associated costs. The company is currently focused on treating prostate cancer. The first drug candidate Sophia has put forward uses an independent anti-tumor chemotype, HDACi, and exploits prostate tumor androgen receptors (AR) for a more selective delivery than existing drugs. By exploiting these receptors, the drug resolves the issue of insufficient accumulation in the tumor and localizes the effects of the HDACi.